Related Experiment Video
Updated: Jul 16, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
[Alveolar hemorrhage secondary to generalized systemic lupus erithematosus treated with recombinant activated factor
Raúl Carrillo-Esper1, Sandra Elizondo-Argueta, Martín de Jesús Sánchez-Zúñiga
1Unidad de Terapia Intensiva, Hospital Angeles Lomas, Vialidad de la Barranca s/n, Colonia Valle de las Palmas, 52763, Huixquilucan, Estado de México, México. seconcapcma@mail.medinet.net.mx
Abstract:
Alveolar hemorrhage is a severe complication of systemic lupus erithematosus (SLe) associated with high mortality. Treatment includes administration of steroids and cyclophosphamide. Additionally, some reports have recommended the use of plasmapheresis, azathioprine and methotrexate. There is a single case reported in the literature in which recombinant activatedfactor VII (rFVIIa) was used to control severe hemorrhage secondary to alveolitis unresponsive to standard treatment. We report the case of a patient with SLE who developed severe alveolar hemorrhage unresponsive to standard measures, but who was successfully treated with rFVIIa.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Hemorrhagic Stroke ll: Pathophysiology
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
